Related Experiment Video
Updated: Aug 23, 2026

Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells
Published on: February 24, 2014
Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells
1Department of Medicine and the Cancer Center, University of California at San Diego, La Jolla, California 92093-0812, USA.
Abstract:
Loss of DNA mismatch repair is a common finding in many types of sporadic human cancers as well as in tumors arising in patients with hereditary nonpolyposis colon cancer. The effect of the loss of DNA mismatch repair activity on sensitivity to a panel of commonly used chemotherapeutic agents was tested using one pair of cell lines proficient or deficient in mismatch repair due to loss of hMSH2 function and another due to loss of hMLH1 function. 6-Thioguanine and N-methyl-N'-nitro-N-nitrosoguanidine, to which these cells are known to be resistant, were included in the panel as controls. The results were concordant in both pairs of cells. Loss of either hMSH2 or hMLH1 function was associated with low level resistance to cisplatin, carboplatin, and etoposide, but there was no resistance to melphalan, perfosfamide, 5-fluorouracil, doxorubicin, or paclitaxel. The results are consistent with the concept that the DNA mismatch repair proteins function as a detector for adducts produced by 6-thioguanine, N-methyl-N'-nitro-N-nitrosoguanidine, cisplatin, and carboplatin but not for melphalan and perfosfamide. They also suggest that these proteins play a role in detecting the DNA damage produced by the binding of etoposide to topoisomerase II and propagating signals that contribute to activation of apoptosis.
Insights
Loss of DNA mismatch repair (MMR) proteins like hMSH2 or hMLH1 confers resistance to certain chemotherapy drugs, including cisplatin and etoposide. This highlights MMR
Area of Science:
- Molecular Biology
- Cancer Research
- Genetics
Background:
- DNA mismatch repair (MMR) deficiency is prevalent in various cancers.
- MMR proteins are crucial for genomic stability and DNA repair.
- Understanding MMR's role in chemotherapy resistance is vital for treatment strategies.
Purpose of the Study:
- To investigate the impact of MMR deficiency on cellular sensitivity to diverse chemotherapeutic agents.
- To determine which DNA damaging agents are recognized by MMR proteins.
Main Methods:
- Utilized cell lines with proficient and deficient DNA mismatch repair (hMSH2 or hMLH1 loss).
- Assessed drug sensitivity across a panel of common chemotherapeutic agents.
- Included known resistant agents (6-thioguanine, N-methyl-N'-nitro-N-nitrosoguanidine) as controls.
Main Results:
- MMR deficiency resulted in low-level resistance to cisplatin, carboplatin, and etoposide.
- No significant resistance was observed for melphalan, perfosfamide, 5-fluorouracil, doxorubicin, or paclitaxel.
- Results were consistent across cell lines deficient in hMSH2 and hMLH1.
Conclusions:
- DNA mismatch repair proteins likely detect DNA adducts from specific agents like cisplatin and carboplatin.
- MMR proteins may play a role in recognizing etoposide-induced DNA damage and apoptosis signaling.
- MMR status influences cellular response to certain DNA-damaging chemotherapies.
Related Concept Videos
Mismatch Repair
Mismatch Repair
DNA Damage can Stall the Cell Cycle
Treatment Resistant Cancers
Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
DNA Damage Can Stall the Cell Cycle

